Zobrazeno 1 - 10
of 128
pro vyhledávání: '"Pre-XDR TB"'
Autor:
Elisha Paikray, Manoranjan Pattnaik, Vedvyas Mishra, Parida Ansuman Abhisek, Shweta Supriya Pradhan, Anima Rout
Publikováno v:
Journal of Family Medicine and Primary Care, Vol 13, Iss 10, Pp 4684-4692 (2024)
Background The foremost concern and challenge in managing drug-resistant tuberculosis is ensuring a high health-related quality of life (HRQoL). The effectiveness of pre-extensively drug-resistant (Pre-XDR) tuberculosis management hinges on patients
Externí odkaz:
https://doaj.org/article/402f329d459f450f82691f61abe41ce8
Autor:
S. B. Patil, M. Tamirat, K. Khazhidinov, E. Ardizzoni, M. Atger, A. Austin, E. Baudin, M. Bekhit, S. Bektasov, E. Berikova, M. Bonnet, R. Caboclo, M. Chaudhry, V. Chavan, S. Cloez, J. Coit, S. Coutisson, Z. Dakenova, B. C. De Jong, C. Delifer, S. Demaisons, J. M. Do, D. Dos Santos Tozzi, V. Ducher, G. Ferlazzo, M. Gouillou, U. Khan, M. Kunda, N. Lachenal, A. N. LaHood, L. Lecca, M. Mazmanian, H. McIlleron, M. Moreau, M. Moschioni, P. Nahid, E. Osso, L. Oyewusi, S. Panda, A. Pâquet, P. Thuong Huu, L. Pichon, M. L. Rich, P. Rupasinghe, N. Salahuddin, E. Sanchez Garavito, K. J. Seung, G. E. Velásquez, M. Vallet, F. Varaine, F. J. Yuya-Septoh, C. D. Mitnick, L. Guglielmetti
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Background Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicit
Externí odkaz:
https://doaj.org/article/2bb066dc17d74fc58700a32bcf0b5485
Autor:
Chawangwa Modongo, Ivan Barilar, Qiao Wang, Tuduetso Molefi, Topo Makhondo, Stefan Niemann, Sanghyuk S. Shin
Publikováno v:
Emerging Infectious Diseases, Vol 29, Iss 11, Pp 2403-2406 (2023)
GeneXpert MTB/RIF, a tool widely used for diagnosing tuberculosis, has limitations for detecting rifampin resistance in certain variants. We report transmission of a pre–extensively drug-resistant variant in Botswana that went undetected by GeneXpe
Externí odkaz:
https://doaj.org/article/2206016cbb1a4b55b8c887dcee98d388
Autor:
Niccolò Riccardi, Roberta Maria Antonello, Maurizio Ferrarese, Alice Repossi, Laura Saderi, Giovanni Fumagalli, Giorgio Besozzi, Giovanni Sotgiu, Luigi Codecasa
Publikováno v:
Monaldi Archives for Chest Disease (2024)
Tuberculosis (TB) diagnosis and management in special populations remain challenging. Data about TB and transgender individuals is scarce, and strategies aimed at reducing the TB burden in this at-risk group are needed. We conducted an observational
Externí odkaz:
https://doaj.org/article/fa526ffb110045c8b6044a70776428c5
Autor:
Isaac Darko Otchere, Portia Abena Morgan, Prince Asare, Stephen Osei-Wusu, Samuel Yaw Aboagye, Stephen Ofori Yirenkyi, Abdul Basit Musah, Emelia Konadu Danso, Georgina Tetteh-Ocloo, Theophilus Afum, Adwoa Asante-Poku, Clement Laryea, Yaw Adusi Poku, Frank Bonsu, Sebastien Gagneux, Dorothy Yeboah-Manu
Publikováno v:
Frontiers in Microbiology, Vol 13 (2023)
BackgroundResistance to tuberculosis (TB) drugs has become a major threat to global control efforts. Early case detection and drug susceptibility profiling of the infecting bacteria are essential for appropriate case management. The objective of this
Externí odkaz:
https://doaj.org/article/747929df9e4f4fdb8d20624f83dfb848
Autor:
Thi Mai Phuong Nguyen, Binh Hoa Nguyen, Thi Thanh Thuy Hoang, Hoang Anh Nguyen, Dinh Hoa Vu, Mai Hoa Nguyen, Bao Ngoc Nguyen, Tom Decroo, Viet Nhung Nguyen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The World health organization (WHO) recently recommended standardized all-oral shorter regimens for rifampicin resistant Tuberculosis (RR-TB). For highly resistant Tuberculosis patients such as pre-XDR-TB: RR-TB plus additional resistance
Externí odkaz:
https://doaj.org/article/3f67da2310a34d6f89e1bb78d6074faf
Autor:
Malaisamy Muniyandi, Paranchi Murugesan Ramesh, William A. Wells, Umesh Alavadi, Suvanand Sahu, Chandrasekaran Padmapriyadarsini
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 8, Iss 8, p 411 (2023)
Objective: To measure the economic impacts of the longer pre-XDR-TB treatment regimen and the shorter BEAT-TB India regimen. Methods: In the current study, the economic impacts of the current 18-month pre-XDR-TB treatment regimen and the 6–9 month
Externí odkaz:
https://doaj.org/article/8364645f731f4b13bdc32877c4faf795
Autor:
Eunjin Cho, Su jin Lee, Jiyoung Lim, Dong Sik Kim, Namil Kim, Han Oh Park, Ji-im Lee, Eunsoon Son, Sang Nae Cho, Wah Wah Aung, Jong Seok Lee
Publikováno v:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 27, Iss , Pp 100303- (2022)
This study evaluated the diagnostic performance of the AccuPower® TB&MDR Real-Time PCR (TBMDR®) and AccuPower® XDR-TB Real-Time PCR Kit-A (XDRA®) to detect multidrug-resistant (MDR-TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB)
Externí odkaz:
https://doaj.org/article/5ae5a2e41dbb467381e32c3fe331001b
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-6 (2020)
Abstract Background Fluoroquinolones (FQs) are potential drugs that inhibit DNA synthesis and are used in the treatment of multidrug-resistant tuberculosis (TB) and short-term anti-TB regimens. In recent years, a high proportion of FQ resistance has
Externí odkaz:
https://doaj.org/article/75607401e95c431eaa693440eb362c95
Autor:
Niccolò Riccardi, Riccardo Alagna, Laura Saderi, Maurizio Ferrarese, Paola Castellotti, Ester Mazzola, Saverio De Lorenzo, Pietro Viggiani, Zarir Udwadia, Giorgio Besozzi, Daniela Cirillo, Giovanni Sotgiu, Luigi Codecasa, for StopTB Italia Onlus Group
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background The increased incidence of drug-resistant TB is a major challenge for effective TB control. Limited therapeutic options and poor treatment outcomes of DR-TB may increase drug-resistance rates. The objective of the study is to retr
Externí odkaz:
https://doaj.org/article/00b6da66088c4261932e865a095be015